Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: Role of NMDA vs. 5-HT1A receptors

European Journal of Neuroscience

Volumn 36, Issue 9, 2012, Pages 3224-3234

  Paquette, Melanie A ^a,b,c,d   Martinez, Alex A ^a   Macheda, Teresa ^a   Meshul, Charles K ^b,c   Johnson, Steven W ^b,c   Berger, S Paul ^c   Giuffrida, Andrea ^a  

^a University of Texas Health Science Center   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

6 hydroxydopamine; Dyskinesia; L DOPA; Parkinson's disease; Serotonin

Indexed keywords

AMANTADINE; DEXTROMETHORPHAN; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDYSKINETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DYSKINESIA; FUNCTIONAL ASSESSMENT; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION; TASK PERFORMANCE;

AMANTADINE; ANIMALS; ANTIPARKINSON AGENTS; CYCLOSERINE; DEXTROMETHORPHAN; DOPAMINE AGENTS; DYSKINESIAS; LEVODOPA; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; PIPERAZINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS;

EID: 84868585089     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2012.08243.x     Document Type: Article

References (69)

1. Baptista, T., López, M.E., Teneud, L., Contreras, Q., Alastre, T., de Quijada, M., Araujo de Baptista, E., Alternus, M., Weiss, S.R., Musseo, E., Páez, X. & Hernández, L. (1997) Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. Pharmacopsychiatry, 30, 43-54.
2. Bishop, C., Taylor, J.L., Kuhn, D.M., Eskow, K.L., Park, J.Y. & Walker, P.D. (2006) MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur. J. Neurosci., 23, 2669-2676.
3. Black, M.D., Crossman, A.R., Hayes, A.G. & Elliott, P.J. (1994) Acute and chronic behavioural sequelae resulting from intrastriatal injection of an NMDA agonist. Pharmacol. Biochem. Behav., 48, 441-446.
4. Blanchet, P.J., Papa, S.M., Metman, L.V., Mouradian, M.M. & Chase, T.N. (1997) Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci. Biobehav. Rev., 21, 447-453.
5. Bonifati, V., Fabrizio, E., Cipriani, R., Vanacore, N. & Meco, G. (1994) Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol., 17, 73-82.
6. Carlsson, T., Carta, M., Winkler, C., Björklund, A. & Kirik, D. (2007) Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci., 27, 8011-8022.
7. Carta, M., Lindgren, H.S., Lundblad, M., Stancampiano, R., Fadda, F. & Cenci, M.A. (2006) Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem., 96, 1718-1727.
8. Carta, M., Carlsson, T., Kirik, D. & Björklund, A. (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain, 130, 1819-1833.
9. Cenci, M.A., Lee, C.S. & Björklund, A. (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci., 10, 2694-2706.
10. Chang, J.W., Wachtel, S.R., Young, D. & Kang, U.J. (1999) Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience, 88, 612-628.
11. Chase, T.N., Oh, J.D. & Konitsiotis, S. (2000) Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol., 247(Suppl. 2), II36-II42.
12. Church, J., Sawyer, D. & McLarnon, J.G. (1994) Interactions of dextromethorphan with the N-methyl-d-aspartate receptor-channel complex: single channel recordings. Brain Res., 666, 189-194.
13. Cobb, W.S. & Abercrombie, E.D. (2003) Differential regulation of somatodendritic and nerve terminal dopamine release by serotonergic innervation of substantia nigra. J. Neurochem., 84, 576-584.
14. Dekundy, A., Lundblad, M., Danysz, W. & Cenci, M.A. (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds. Behav. Brain Res., 179, 76-89.
15. Del Dotto, P., Pavese, N., Gambaccini, G., Bernardini, S., Metman, L.V., Chase, T.N. & Bonuccelli, U. (2001) Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov. Disord., 16, 515-520.
16. Depoortere, R., Perrault, G. & Sanger, D.J. (1999) Prepulse inhibition of the startle reflex in rats: effects of compounds acting at various sites on the NMDA receptor complex. Behav. Pharmacol., 10, 51-62.
17. Dupre, K.B., Eskow, K.L., Negron, G. & Bishop, C. (2007) The differential effects of 5-HT (1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res., 1158, 135-143.
18. Dupre, K.B., Eskow, K.L., Steiniger, A., Klioueva, A., Negron, G.E., Lormand, L., Park, J.Y. & Bishop, C. (2008) Effects of coincident 5-HT(1A) receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl), 199, 99-108.
19. Eskow, K.L., Gupta, V., Alam, S., Park, J.Y. & Bishop, C. (2007) The partial 5-HT(1A) agonist buspirone reduces the expression and development of L-DOPA-induced dyskinesia in rats and improves L-DOPA efficacy. Pharmacol. Biochem. Behav., 87, 306-314.
20. Eskow, K.L., Dupre, K.B., Barnum, C.J., Dickinson, S.O., Park, J.Y. & Bishop, C. (2009) The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse, 63, 610-620.
21. Frechilla, D., Cobreros, A., Saldise, L., Moratalla, R., Insausti, R., Luquin, M. & Del Río, J. (2001) Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse, 39, 288-296.
22. Gaikwad, R.V., Gaonkar, R.K., Jadhav, S.A., Thorat, V.M., Jadhav, J.H. & Balsara, J.J. (2005) Involvement of central serotonergic systems in dextromethorphan-induced behavioural syndrome in rats. Indian J. Exp. Biol., 43, 620-625.
23. Goetz, C.G., Damier, P., Hicking, C., Laska, E., Müller, T., Olanow, C.W., Rascol, O. & Russ, H. (2007) Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov. Disord., 22, 179-186.
24. Iravani, M.M., Jackson, M.J., Kuoppamäki, M., Smith, L.A. & Jenner, P. (2003) 3, 4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated primates. J. Neurosci., 23, 9107-9115.
25. Iravani, M.M., Tayarani-Binazir, K., Chu, W.B., Jackson, M.J. & Jenner, P. (2006) In 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1A agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J. Pharmacol. Exp. Ther., 319, 1225-1234.
26. Kamei, J. (1996) Role of opioidergic and serotonergic mechanisms in cough and antitussives. Pulm. Pharmacol., 9, 349-356.
27. Kamei, J., Mori, T., Igarashi, H. & Kasuya, Y. (1991) Effects of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective agonist of 5-HT1A receptors, on the cough reflex in rats. Eur. J. Pharmacol., 203, 253-258.
28. Kannari, K., Tanaka, H., Maeda, T., Tomiyama, M., Suda, T. & Matsunaga, M. (2000) Reserpine pretreatment prevents increases in extracellular striatal dopamine following l-DOPA administration in rats with nigrostriatal denervation. J. Neurochem., 74, 263-269.
29. Kannari, K., Kurahashi, K., Tomiyama, M., Maeda, T., Arai, A., Baba, M., Suda, T. & Matsunaga, M. (2002) Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei, 54, 133-137.
30. Kelland, M.D., Freeman, A.S. & Chiodo, L.A. (1990) Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J. Pharmacol. Exp. Ther., 253, 803-811.
31. Kornhuber, J., Bormann, J., Hübers, M., Rusche, K. & Riederer, P. (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur. J. Pharmacol., 25, 297-300.
32. Kumar, R., Riddle, L.R., Griffin, S.A., Chu, W., Vangveravong, S., Neisewander, J., Mach, R.H. & Luedtke, R.R. (2009a) Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology, 56, 956-969.
33. Kumar, R., Riddle, L., Griffin, S.A., Grundt, P., Newman, A.H. & Luedtke, R.R. (2009b) Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology, 56, 944-955.
34. Lindgren, H.S., Andersson, D.R., Lagerkvist, S., Nissbrandt, H. & Cenci, M.A. (2010) L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem., 112, 1465-1476.
35. Lindner, M.D., Plone, M.A., Francis, J.M. & Emerich, D.F. (1996) Validation of a rodent model of Parkinson's Disease: evidence of a therapeutic window for oral Sinemet. Brain Res. Bull., 39, 367-372.
36. Lundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N. & Cenci, M.A. (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci., 15, 120-132.
37. Lundblad, M., Usiello, A., Carta, M., Hkanssond, K., Fisoned, G. & Cenci, M.A. (2005) Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp. Neurol., 194, 66-75.
38. Marin, C., Jimenez, A., Bonastre, M., Chase, T.N. & Tolosa, E. (2000) Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Synapse, 36, 267-274.
39. Mela, F., Marti, M., Bido, S., Cenci, M.A. & Morari, M. (2012) In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiol. Dis., 45, 573-582.
40. Meoni, P., Tortella, F.C. & Bowery, N.G. (1997) An autoradiographic study of dextromethorphan high-affinity binding sites in rat brain: sodium-dependency and colocalization with paroxetine. Br. J. Pharmacol., 120, 1255-1262.
41. Metman, L.V., Del Dotto, P., LePoole, K., Konitsiotis, S., Fang, J. & Chase, T.N. (1999) Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch. Neurol., 56, 1383-1386.
42. Miller, S.C. (2005) Dextromethorphan psychosis, dependence and physical withdrawal. Addict. Biol., 10, 325-327.
43. Monville, C., Torres, E.M. & Dunnett, S.B. (2005) Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res. Bull., 68, 16-23.
44. Moregese, M.G., Cassano, T., Cuomo, V. & Giuffrida, A. (2007) Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp. Neurol., 208, 110-119.
45. Moregese, M.G., Cassano, T., Gaetani, S., Macheda, T., Laconca, L., Dipasquale, P., Ferraro, L., Antonelli, T., Cuomo, V. & Giuffrida, A. (2009) Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55, 212-2. Neurochem. Int., 54, 56-64.
46. Netzer, R., Pflimlin, P. & Trube, G. (1993) Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. Eur. J. Pharmacol., 238, 209-216.
47. Olanow, C.W., Damier, P., Goetz, C.G., Mueller, T., Nutt, J., Rascol, O., Serbanescu, A., Deckers, F. & Russ, H. (2004) Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias: the SPLENDID Study. Clin. Neuropharmacol., 27, 58-62.
48. Onogi, H., Ishigaki, S., Nakagawasai, O., Arai-Kato, Y., Arai, Y., Watanabe, H., Miyamoto, A., Tan-no, K. & Tadano, T. (2009) Influence of memantine on brain monoaminergic neurotransmission parameters in mice: neurochemical and behavioral study. Biol. Pharm. Bull., 32, 850-855.
49. Paillé, V., Henry, V., Lescaudron, L., Brachet, P. & Damier, P. (2007) Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Mov. Disord., 22, 533-539.
50. Paquette, M.A., Brudney, E.G., Putterman, D.B., Meshul, C.K., Johnson, S.W. & Berger, S.P. (2008) Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias. NeuroReport, 19, 111-115.
51. Paquette, M.A., Foley, K., Brudney, E.G., Meshul, C.K., Johnson, S.W. & Berger, S.P. (2009a) The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology, 204, 743-754.
52. Paquette, M.A., Marsh, S.T., Hutchings, J.E. & Castañeda, E. (2009b) Amphetamine-evoked rotation requires newly-synthesized dopamine at 14days but not 1day after intranigral 6-OHDA and is consistently dissociated from sensorimotor behavior. Behav. Brain Res., 200, 197-207.
53. Paquette, M.A., Anderson, A.M., Lewis, J.R., Meshul, C.K., Johnson, S.W. & Berger, S.P. (2010) MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism. Neuropharmacology, 58, 1002-1008.
54. Parsons, C.G., Quack, G., Bresink, I., Baran, L., Przegalinski, E., Kostowski, W., Krzascik, P., Hartmann, S. & Danysz, W. (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology, 34, 1239-1258.
55. Riddle, L.R., Kumar, R., Griffin, S.A., Grundt, P., Newman, A.H. & Luedtke, R.R. (2011) Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats. Neuropharmacology, 60, 284-294.
56. Rylander, D., Parent, M., O'Sullivan, S.S., Dovero, S., Lees, A.J., Bezard, E., Descarries, L. & Cenci, M.A. (2010) Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol., 68, 619-628.
57. Schallert, T., Fleming, S.M., Leasure, J.L., Tillerson, J.L. & Bland, S.T. (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology, 39, 777-787.
58. Shearman, E., Rossi, S., Szasz, B., Juranyi, Z., Fallon, S., Pomara, N., Sershen, H. & Lajtha, A. (2006) Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. Brain Res. Bull., 69, 204-213.
59. Sills, M.A. & Loo, P.S. (1989) Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate. Mol. Pharmacol., 36, 160-165.
60. Tanaka, H., Kannari, K., Maeda, T., Tomiyama, M., Suda, T. & Matsunaga, M. (1999) Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. NeuroReport, 10, 631-634.
61. Tomiyama, M., Kimura, T., Maeda, T., Kannari, K., Matsunaga, M. & Baba, M. (2005) A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. Neurosci. Res., 52, 185-194.
62. Ungerstedt, U. (1971) Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol. Scand. Suppl., 367, 49-68.
63. Verhagen Metman, L., Blanchet, P.J., van den Munckhof, P., Del Dotto, P., Natté, R. & Chase, T.N. (1998a) A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov. Disord., 13, 414-417.
64. Verhagen Metman, L., Del Dotto, P., van den Munckhof, P., Fang, J., Mouradian, M.M. & Chase, T.N. (1998b) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology, 50, 1323-1326.
65. Verhagen Metman, L., Del Dotto, P., Natté, R., van den Munckhof, P. & Chase, T.N. (1998c) Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology, 51, 203-206.
66. Verhagen Metman, L., Del Dotto, P., Blanchet, P.J., van den Munckhof, P. & Chase, T.N. (1998b) Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in PD. Amino Acids, 14, 75-82.
67. Walker, D.L., Ressler, K.J., Lu, K.T. & Davis, M. (2002) Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J. Neurosci., 22, 2343-2351.
68. Werling, L.L., Keller, A., Frank, J.G. & Nuwayhid, S.J. (2007) A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp. Neurol., 207, 248-257.
69. Winkler, C., Kirik, D., Björklund, A. & Cenci, M.A. (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis., 10, 165-186.